Vasa vasorum in atherosclerosis and clinical significance

International Journal of Molecular Sciences

Volumn 16, Issue 5, 2015, Pages 11574-11608

  Xu, Junyan ^a   Lu, Xiaotong ^a   Shi, Guo Ping ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenic therapy; Atherosclerosis; Imaging modality; Mechanism; Neovascularization; Vasa vasorum

Indexed keywords

CHOLESTEROL; IODINE 125; IRON; PROTEINASE; TECHNETIUM 99M; ANGIOGENESIS INHIBITOR;

ATHEROGENESIS; ATHEROSCLEROSIS; BASEMENT MEMBRANE; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ENDOTHELIUM CELL; HUMAN; HYPOXIA; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; REVIEW; THROMBOSIS; VASA VASORUM; ANIMAL; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROGNOSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ATHEROSCLEROSIS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; VASA VASORUM;

EID: 84930672493     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160511574     Document Type: Review

References (190)

1. Mozaffarian, D.; Benjamin, E.J.; Go, A.S.; Arnett, D.K.; Blaha, M.J.; Cushman, M.; de Ferranti, S.; Despres, J.P.; Fullerton, H.J.; Howard, V.J.;et al.Heart disease and stroke statistics—2015 update: A report from the American Heart Association. Circulation 2015, 131, e29–e322.
2. Davies, M.J.; Richardson, P.D.; Woolf, N.; Katz, D.R.; Mann, J. Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J. 1993, 69, 377–381.
3. De Boer, O.J.; van der Wal, A.C.; Teeling, P.; Becker, A.E. Leucocyte recruitment in rupture prone regions of lipid-rich plaques: A prominent role for neovascularization? Cardiovasc. Res. 1999, 41, 443–449.
4. Staub, D.; Patel, M.B.; Tibrewala, A.; Ludden, D.; Johnson, M.; Espinosa, P.; Coll, B.; Jaeger, K.A.; Feinstein, S.B. Vasa vasorum and plaque neovascularization on contrast-enhanced carotid ultrasound imaging correlates with cardiovascular disease and past cardiovascular events. Stroke J. Cereb. Circ. 2010, 41, 41–47.
5. Takano, M.; Mizuno, K.; Okamatsu, K.; Yokoyama, S.; Ohba, T.; Sakai, S. Mechanical and structural characteristics of vulnerable plaques: Analysis by coronary angioscopy and intravascular ultrasound. J. Am. Coll. Cardiol. 2001, 38, 99–104.
6. Ritman, E.L.; Lerman, A. The dynamic vasa vasorum. Cardiovasc. Res. 2007, 75, 649–658.
7. Koester, W. Endareritis and arteritis. Berl. Klin. Wochenschr. 1876, 13, 454–455.
8. Paterson, J.C. Vascularization and hemorrhage of the intima of arteriosclerotic coronary arteries. Arch. Pathol. 1936, 22, 313–324.
9. Patterson, J.C. Capillary rupture with intimal hemorrhage as a causative factor in coronary thrombosis. Arch. Pathol. 1938, 25, 474–487.
10. Barger, A.C.; Beeuwkes, R., 3rd; Lainey, L.L.; Silverman, K.J. Hypothesis: Vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N. Engl. J. Med. 1984, 310, 175–177.
11. Gossl, M.; Versari, D.; Hildebrandt, H.A.; Bajanowski, T.; Sangiorgi, G.; Erbel, R.; Ritman, E.L.; Lerman, L.O.; Lerman, A. Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis. JACC Cardiovasc. Imaging 2010, 3, 32–40.
12. Kwon, H.M.; Sangiorgi, G.; Ritman, E.L.; McKenna, C.; Holmes, D.R., Jr.; Schwartz, R.S.; Lerman, A. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J. Clin. Investig. 1998, 101, 1551–1556.
13. Dunmore, B.J.; McCarthy, M.J.; Naylor, A.R.; Brindle, N.P. Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. J. Vasc. Surg. 2007, 45, 155–159.
14. Sluimer, J.C.; Kolodgie, F.D.; Bijnens, A.P.; Maxfield, K.; Pacheco, E.; Kutys, B.; Duimel, H.; Frederik, P.M.; van Hinsbergh, V.W.; Virmani, R.;et al. Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J. Am. Coll. Cardiol. 2009, 53, 1517–1527.
15. Khurana, R.; Zhuang, Z.; Bhardwaj, S.; Murakami, M.; de Muinck, E.; Yla-Herttuala, S.; Ferrara, N.; Martin, J.F.; Zachary, I.; Simons, M. Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation 2004, 110, 2436–2443.
16. Herrmann, J.; Lerman, L.O.; Rodriguez-Porcel, M.; Holmes, D.R., Jr.; Richardson, D.M.; Ritman, E.L.; Lerman, A. Coronary vasa vasorum neovascularization precedes epicardial endothelial dysfunction in experimental hypercholesterolemia. Cardiovasc. Res. 2001, 51, 762–766.
17. Maiellaro, K.; Taylor, W.R. The role of the adventitia in vascular inflammation. Cardiovasc. Res. 2007, 75, 640–648.
18. Clarke, J.A. An X-ray microscopic study of the postnatal development of the vasa vasorum of normal human coronary arteries. Acta Anat. 1966, 64, 506–516.
19. Wolinsky, H.; Glagov, S. Nature of species differences in the medial distribution of aortic vasa vasorum in mammals. Circ. Res. 1967, 20, 409–421.
20. Schoenenberger, F.; Mueller, A. On the vascularization of the bovine aortic wall. Helv. Physiol. Pharmacol. Acta 1960, 18, 136–150.
21. Gossl, M.; Rosol, M.; Malyar, N.M.; Fitzpatrick, L.A.; Beighley, P.E.; Zamir, M.; Ritman, E.L. Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries. Anat. Rec. Part A Discov. Mol. Cell. Evol. Biol. 2003, 272, 526–537.
22. Fleiner, M.; Kummer, M.; Mirlacher, M.; Sauter, G.; Cathomas, G.; Krapf, R.; Biedermann, B.C. Arterial neovascularization and inflammation in vulnerable patients: Early and late signs of symptomatic atherosclerosis. Circulation 2004, 110, 2843–2850.
23. Bitar, R.; Moody, A.R.; Leung, G.; Symons, S.; Crisp, S.; Butany, J.; Rowsell, C.; Kiss, A.; Nelson, A.; Maggisano, R. In vivo 3D high-spatial-resolution MR imaging of intraplaque hemorrhage. Radiology 2008, 249, 259–267.
24. Acoltzin Vidal, C.; Maldonado Villasenor, I.; Rodriguez Cisneros, L.; Muniz Murguia, J.J. Diminished vascular density in the aortic wall. Morphological and functional characteristics of atherosclerosis. Arch. Cardiol. Mexico 2004, 74, 176–180.
25. Rademakers, T.; Douma, K.; Hackeng, T.M.; Post, M.J.; Sluimer, J.C.; Daemen, M.J.; Biessen, E.A.; Heeneman, S.; van Zandvoort, M.A. Plaque-associated vasa vasorum in aged apolipoprotein E-deficient mice exhibit proatherogenic functional features in vivo. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 249–256.
26. Gossl, M.; Malyar, N.M.; Rosol, M.; Beighley, P.E.; Ritman, E.L. Impact of coronary vasa vasorum functional structure on coronary vessel wall perfusion distribution. Am. J. Physiol. Heart Circ. Physiol. 2003, 285, H2019–H2026.
27. Han, D.G. The innateness of coronary artery: Vasa vasorum. Med. Hypotheses 2010, 74, 443–444.
28. Moss, A.J.; Samuelson, P.; Angell, C.; Minken, S.L. Polarographic evaluation of transmural oxygen availabitlity in intact muscular arteries. J. Atheroscler. Res. 1968, 8, 803–810.
29. Crawford, D.W.; Back, L.H.; Cole, M.A. In vivo oxygen transport in the normal rabbit femoral arterial wall. J. Clin. Investig. 1980, 65, 1498–1508.
30. Bratzler, R.L.; Chisolm, G.M.; Colton, C.K.; Smith, K.A.; Lees, R.S. The distribution of labeled low-density lipoproteins across the rabbit thoracic aorta in vivo. Atherosclerosis 1977, 28, 289–307.
31. Scotland, R.S.; Vallance, P.J.; Ahluwalia, A. Endogenous factors involved in regulation of tone of arterial vasa vasorum: Implications for conduit vessel physiology. Cardiovasc. Res. 2000, 46, 403–411.
32. Scotland, R.; Vallance, P.; Ahluwalia, A. Endothelin alters the reactivity of vasa vasorum: Mechanisms and implications for conduit vessel physiology and pathophysiology. Br. J. Pharmacol. 1999, 128, 1229–1234.
33. Ohhira, A.; Ohhashi, T. Effects of aortic pressure and vasoactive agents on the vascular resistance of the vasa vasorum in canine isolated thoracic aorta. J. Physiol. 1992, 453, 233–245.
34. Vio, A.; Gozzetti, G.; Reggiani, A. Importance of the vasa vasorum in the healing processes of arterial sutures. (Experimental study on the dog). Boll. Soc. Ital. Biol. Sper. 1967, 43, 88–90.
35. Winternitz, M.C.; Thomas, R.M.; LeCompte, P.M. The Biology of Arteriosclerosis; Springfield: Prince George’s County, MA, USA, 1938.
36. Ribatti, D.; Levi-Schaffer, F.; Kovanen, P.T. Inflammatory angiogenesis in atherogenesis— A double-edged sword. Ann. Med. 2008, 40, 606–621.
37. Williams, J.K.; Armstrong, M.L.; Heistad, D.D. Vasa vasorum in atherosclerotic coronary arteries: Responses to vasoactive stimuli and regression of atherosclerosis. Circ. Res. 1988, 62, 515–523.
38. Sano, M.; Sasaki, T.; Hirakawa, S.; Sakabe, J.; Ogawa, M.; Baba, S.; Zaima, N.; Tanaka, H.; Inuzuka, K.; Yamamoto, N.; et al. Lymphangiogenesis and angiogenesis in abdominal aortic aneurysm. PLoS ONE 2014, 9, e89830.
39. Davie, N.J.; Gerasimovskaya, E.V.; Hofmeister, S.E.; Richman, A.P.; Jones, P.L.; Reeves, J.T.; Stenmark, K.R. Pulmonary artery adventitial fibroblasts cooperate with vasa vasorum endothelial cells to regulate vasa vasorum neovascularization: A process mediated by hypoxia and endothelin-1. Am. J. Pathol. 2006, 168, 1793–1807.
40. Bjornheden, T.; Levin, M.; Evaldsson, M.; Wiklund, O. Evidence of hypoxic areas within the arterial wall in vivo. Arterioscler. Thromb. Vasc. Biol. 1999, 19, 870–876.
41. Nakashima, Y.; Chen, Y.X.; Kinukawa, N.; Sueishi, K. Distributions of diffuse intimal thickening in human arteries: Preferential expression in atherosclerosis-prone arteries from an early age. Virchows Arch. Int. J. Pathol. 2002, 441, 279–288.
42. Zemplenyi, T.; Crawford, D.W.; Cole, M.A. Adaptation to arterial wall hypoxia demonstrated in vivo with oxygen microcathodes. Atherosclerosis 1989, 76, 173–179.
43. Jarvilehto, M.; Tuohimaa, P. Vasa vasorum hypoxia: Initiation of atherosclerosis. Med. Hypotheses 2009, 73, 40–41.
44. Den Hartog, J.P. Strength of Materials; Dover Publications, Inc.: New York, NY, USA, 1949; p. 323.
45. Bjornheden, T.; Bondjers, G. Oxygen consumption in aortic tissue from rabbits with diet-induced atherosclerosis. Arteriosclerosis 1987, 7, 238–247.
46. Sluimer, J.C.; Gasc, J.M.; van Wanroij, J.L.; Kisters, N.; Groeneweg, M.; Sollewijn Gelpke, M.D.; Cleutjens, J.P.; van den Akker, L.H.; Corvol, P.; Wouters, B.G.;et al. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J. Am. Coll. Cardiol. 2008, 51, 1258–1265.
47. Kwon, H.M.; Sangiorgi, G.; Ritman, E.L.; Lerman, A.; McKenna, C.; Virmani, R.; Edwards, W.D.; Holmes, D.R.; Schwartz, R.S. Adventitial vasa vasorum in balloon-injured coronary arteries: Visualization and quantitation by a microscopic three-dimensional computed tomography technique. J. Am. Coll. Cardiol. 1998, 32, 2072–2079.
48. Gossl, M.; Versari, D.; Mannheim, D.; Ritman, E.L.; Lerman, L.O.; Lerman, A. Increased spatial vasa vasorum density in the proximal LAD in hypercholesterolemia—Implications for vulnerable plaque-development. Atherosclerosis 2007, 192, 246–252.
49. Sun, Z. Atherosclerosis and atheroma plaque rupture: Imaging modalities in the visualization of vasa vasorum and atherosclerotic plaques. Sci. World J. 2014, 2014, 312764.
50. Gossl, M.; Versari, D.; Lerman, L.O.; Chade, A.R.; Beighley, P.E.; Erbel, R.; Ritman, E.L. Low vasa vasorum densities correlate with inflammation and subintimal thickening: Potential role in location--determination of atherogenesis. Atherosclerosis 2009, 206, 362–368.
51. Lim, C.S.; Kiriakidis, S.; Sandison, A.; Paleolog, E.M.; Davies, A.H. Hypoxia-inducible factor pathway and diseases of the vascular wall. J. Vasc. Surg. 2013, 58, 219–230.
52. Semenza, G.L.; Agani, F.; Booth, G.; Forsythe, J.; Iyer, N.; Jiang, B.H.; Leung, S.; Roe, R.; Wiener, C.; Yu, A. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int. 1997, 51, 553–555.
53. Oikawa, M.; Abe, M.; Kurosawa, H.; Hida, W.; Shirato, K.; Sato, Y. Hypoxia induces transcription factor ETS-1 via the activity of hypoxia-inducible factor-1. Biochem. Biophys. Res. Commun. 2001, 289, 39–43.
54. Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306–1309.
55. Ushio-Fukai, M. VEGF signaling through NADPH oxidase-derived ROS. Antioxid. Redox Signal. 2007, 9, 731–739.
56. Shweiki, D.; Itin, A.; Soffer, D.; Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843–845.
57. Kuwahara, F.; Kai, H.; Tokuda, K.; Shibata, R.; Kusaba, K.; Tahara, N.; Niiyama, H.; Nagata, T.; Imaizumi, T. Hypoxia-inducible factor-1α/vascular endothelial growth factor pathway for adventitial vasa vasorum formation in hypertensive rat aorta. Hypertension 2002, 39, 46–50.
58. Joukov, V.; Pajusola, K.; Kaipainen, A.; Chilov, D.; Lahtinen, I.; Kukk, E.; Saksela, O.; Kalkkinen, N.; Alitalo, K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15, 290–298.
59. Achen, M.G.; Jeltsch, M.; Kukk, E.; Makinen, T.; Vitali, A.; Wilks, A.F.; Alitalo, K.; Stacker, S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA 1998, 95, 548–553.
60. Kaipainen, A.; Korhonen, J.; Mustonen, T.; van Hinsbergh, V.W.; Fang, G.H.; Dumont, D.; Breitman, M.; Alitalo, K. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. USA 1995, 92, 3566–3570.
61. Kukk, E.; Lymboussaki, A.; Taira, S.; Kaipainen, A.; Jeltsch, M.; Joukov, V.; Alitalo, K. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996, 122, 3829–3837.
62. Partanen, T.A.; Arola, J.; Saaristo, A.; Jussila, L.; Ora, A.; Miettinen, M.; Stacker, S.A.; Achen, M.G.; Alitalo, K. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J. 2000, 14, 2087–2096.
63. Rutanen, J.; Leppanen, P.; Tuomisto, T.T.; Rissanen, T.T.; Hiltunen, M.O.; Vajanto, I.; Niemi, M.; Hakkinen, T.; Karkola, K.; Stacker, S.A.; et al. Vascular endothelial growth factor-D expression in human atherosclerotic lesions. Cardiovasc. Res. 2003, 59, 971–979.
64. Belgore, F.; Blann, A.; Neil, D.; Ahmed, A.S.; Lip, G.Y. Localisation of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries. J. Clin. Pathol. 2004, 57, 266–272.
65. Vuorio, T.; Nurmi, H.; Moulton, K.; Kurkipuro, J.; Robciuc, M.R.; Ohman, M.; Heinonen, S.E.; Samaranayake, H.; Heikura, T.; Alitalo, K.;et al. Lymphatic vessel insufficiency in hypercholesterolemic mice alters lipoprotein levels and promotes atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 1162–1170.
66. Iwasaka, C.; Tanaka, K.; Abe, M.; Sato, Y. Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J. Cell. Physiol. 1996, 169, 522–531.
67. Hashiya, N.; Jo, N.; Aoki, M.; Matsumoto, K.; Nakamura, T.; Sato, Y.; Ogata, N.; Ogihara, T.; Kaneda, Y.; Morishita, R. In vivo evidence of angiogenesis induced by transcription factor Ets-1: Ets-1 is located upstream of angiogenesis cascade. Circulation 2004, 109, 3035–3041.
68. Higashida, T.; Kanno, H.; Nakano, M.; Funakoshi, K.; Yamamoto, I. Expression of hypoxia-inducible angiogenic proteins (hypoxia-inducible factor-1α, vascular endothelial growth factor, and E26 transformation-specific-1) and plaque hemorrhage in human carotid atherosclerosis. J. Neurosurg. 2008, 109, 83–91.
69. Kitange, G.; Shibata, S.; Tokunaga, Y.; Yagi, N.; Yasunaga, A.; Kishikawa, M.; Naito, S. Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. Lab. Investig. J. Tech. Methods Pathol. 1999, 79, 407–416.
70. Paumelle, R.; Tulasne, D.; Kherrouche, Z.; Plaza, S.; Leroy, C.; Reveneau, S.; Vandenbunder, B.; Fafeur, V. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene 2002, 21, 2309–2319.
71. −/− double knockout mice. BMC Nephrol. 2010, 11, doi:10.1186/1471-2369-11-18.
72. Kumamoto, M.; Nakashima, Y.; Sueishi, K. Intimal neovascularization in human coronary atherosclerosis: Its origin and pathophysiological significance. Hum. Pathol. 1995, 26, 450–456.
73. Yamashita, A.; Shoji, K.; Tsuruda, T.; Furukoji, E.; Takahashi, M.; Nishihira, K.; Tamura, S.; Asada, Y. Medial andadventitial macrophages are associated with expansive atherosclerotic remodeling in rabbit femoral artery. Histol. Histopathol. 2008, 23, 127–136.
74. Sluimer, J.C.; Daemen, M.J. Novel concepts in atherogenesis: Angiogenesis and hypoxia in atherosclerosis. J. Pathol. 2009, 218, 7–29.
75. Brown, A.J.; Dean, R.T.; Jessup, W. Free and esterified oxysterol: Formation during copper-oxidation of low density lipoprotein and uptake by macrophages. J. Lipid Res. 1996, 37, 320–335.
76. Ho-Tin-Noe, B.; le Dall, J.; Gomez, D.; Louedec, L.; Vranckx, R.; El-Bouchtaoui, M.; Legres, L.; Meilhac, O.; Michel, J.B. Early atheroma-derived agonists of peroxisome proliferator-activated receptor-gamma trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ. Res. 2011, 109, 1003–1014.
77. Sahebkar, A.; Watts, G.F. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin. Ther. 2013, 35, 1082–1098.
78. Lusis, A.J. Atherosclerosis. Nature 2000, 407, 233–241.
79. Kolodgie, F.D.; Gold, H.K.; Burke, A.P.; Fowler, D.R.; Kruth, H.S.; Weber, D.K.; Farb, A.; Guerrero, L.J.; Hayase, M.; Kutys, R.; et al. Intraplaque hemorrhage and progression of coronary atheroma. N. Engl. J. Med. 2003, 349, 2316–2325.
80. Tanaka, K.; Nagata, D.; Hirata, Y.; Tabata, Y.; Nagai, R.; Sata, M. Augmented angiogenesis in adventitia promotes growth of atherosclerotic plaque in apolipoprotein E-deficient mice. Atherosclerosis 2011, 215, 366–373.
81. Moulton, K.S. Angiogenesis in atherosclerosis: Gathering evidence beyond speculation. Curr. Opin. Lipidol. 2006, 17, 548–555.
82. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391, 79–82.
83. Fang, L.; Liu, C.; Miller, Y.I. Zebrafish models of dyslipidemia: Relevance to atherosclerosis and angiogenesis. Transl. Res. J. Lab. Clin. Med. 2014, 163, 99–108.
84. Salomon, R.G.; Hong, L.; Hollyfield, J.G. Discovery of carboxyethylpyrroles (CEPs): Critical insights into AMD, autism, cancer, and wound healing from basic research on the chemistry of oxidized phospholipids. Chem. Res. Toxicol. 2011, 24, 1803–1816.
85. West, X.Z.; Malinin, N.L.; Merkulova, A.A.; Tischenko, M.; Kerr, B.A.; Borden, E.C.; Podrez, E.A.; Salomon, R.G.; Byzova, T.V. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010, 467, 972–976.
86. Chatterjee, T.K.; Stoll, L.L.; Denning, G.M.; Harrelson, A.; Blomkalns, A.L.; Idelman, G.; Rothenberg, F.G.; Neltner, B.; Romig-Martin, S.A.; Dickson, E.W.;et al. Proinflammatory phenotype of perivascular adipocytes: Influence of high-fat feeding. Circ. Res. 2009, 104, 541–549.
87. Barandier, C.; Montani, J.P.; Yang, Z. Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: Effects of aging and obesity. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H1807–H1813.
88. Wang, P.; Xu, T.Y.; Guan, Y.F.; Su, D.F.; Fan, G.R.; Miao, C.Y. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc. Res. 2009, 81, 370–380.
89. Manka, D.; Chatterjee, T.K.; Stoll, L.L.; Basford, J.E.; Konaniah, E.S.; Srinivasan, R.; Bogdanov, V.Y.; Tang, Y.; Blomkalns, A.L.; Hui, D.Y.; Weintraub, N.L. Transplanted perivascular adipose tissue accelerates injury-induced neointimal hyperplasia: Role of monocyte chemoattractant protein-1. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 1723–1730.
90. Rajsheker, S.; Manka, D.; Blomkalns, A.L.; Chatterjee, T.K.; Stoll, L.L.; Weintraub, N.L. Crosstalk between perivascular adipose tissue and blood vessels. Curr. Opin. Pharmacol. 2010, 10, 191–196.
91. Garcia-Touchard, A.; Henry, T.D.; Sangiorgi, G.; Spagnoli, L.G.; Mauriello, A.; Conover, C.; Schwartz, R.S. Extracellular proteases in atherosclerosis and restenosis. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1119–1127.
92. Liu, X.Q.; Mao, Y.; Wang, B.; Lu, X.T.; Bai, W.W.; Sun, Y.Y.; Liu, Y.; Liu, H.M.; Zhang, L.; Zhao, Y.X.;et al. Specific matrix metalloproteinases play different roles in intraplaque angiogenesis and plaque instability in rabbits. PLoS ONE 2014, 9, e107851.
93. Svensson, P.A.; Olson, F.J.; Hagg, D.A.; Ryndel, M.; Wiklund, O.; Karlstrom, L.; Hulthe, J.; Carlsson, L.M.; Fagerberg, B. Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis. Int. J. Mol. Med. 2008, 22, 459–464.
94. Mattock, K.L.; Gough, P.J.; Humphries, J.; Burnand, K.; Patel, L.; Suckling, K.E.; Cuello, F.; Watts, C.; Gautel, M.; Avkiran, M.; et al. Legumain and cathepsin-L expression in human unstable carotid plaque. Atherosclerosis 2010, 208, 83–89.
95. Li, W.; Kornmark, L.; Jonasson, L.; Forssell, C.; Yuan, X.M. Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. Atherosclerosis 2009, 202, 92–102.
96. Le Dall, J.; Ho-Tin-Noe, B.; Louedec, L.; Meilhac, O.; Roncal, C.; Carmeliet, P.; Germain, S.; Michel, J.B.; Houard, X. Immaturity of microvessels in haemorrhagic plaques is associated with proteolytic degradation of angiogenic factors. Cardiovasc. Res. 2010, 85, 184–193.
97. Leclercq, A.; Houard, X.; Philippe, M.; Ollivier, V.; Sebbag, U.; Meilhac, O.; Michel, J.B. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J. Leukoc. Biol. 2007, 82, 1420–1429.
98. Maisonpierre, P.C.; Suri, C.; Jones, P.F.; Bartunkova, S.; Wiegand, S.J.; Radziejewski, C.; Compton, D.; McClain, J.; Aldrich, T.H.; Papadopoulos, N. et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997, 277, 55–60.
99. Hashimoto, T.; Lam, T.; Boudreau, N.J.; Bollen, A.W.; Lawton, M.T.; Young, W.L. Abnormal balance in the angiopoietin-tie2 system in human brain arteriovenous malformations. Circ. Res. 2001, 89, 111–113.
100. Anagnostopoulos, A.; Eleftherakis-Papaiakovou, V.; Kastritis, E.; Tsionos, K.; Bamias, A.; Meletis, J.; Dimopoulos, M.A.; Terpos, E. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: The ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br. J. Haematol. 2007, 137, 560–568.
101. Post, S.; Peeters, W.; Busser, E.; Lamers, D.; Sluijter, J.P.; Goumans, M.J.; de Weger, R.A.; Moll, F.L.; Doevendans, P.A.; Pasterkamp, G.; et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J. Vasc. Res. 2008, 45, 244–250.
102. Chistiakov, D.A.; Orekhov, A.N.; Bobryshev, Y.V. Contribution of neovascularization and intraplaque haemorrhage to atherosclerotic plaque progression and instability. Acta Physiol. 2015, 213, 539–553.
103. Nagy, E.; Eaton, J.W.; Jeney, V.; Soares, M.P.; Varga, Z.; Galajda, Z.; Szentmiklosi, J.; Mehes, G.; Csonka, T.; Smith, A.; et al. Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 1347–1353.
104. Balla, J.; Jacob, H.S.; Balla, G.; Nath, K.; Eaton, J.W.; Vercellotti, G.M. Endothelial-cell heme uptake from heme proteins: Induction of sensitization and desensitization to oxidant damage. Proc. Natl. Acad. Sci. USA 1993, 90, 9285–9289.
105. Potor, L.; Banyai, E.; Becs, G.; Soares, M.P.; Balla, G.; Balla, J.; Jeney, V. Atherogenesis may involve the prooxidant and proinflammatory effects of ferryl hemoglobin. Oxid. Med. Cell. Longev. 2013, 2013, doi:10.1155/2013/676425.
106. Juckett, M.B.; Balla, J.; Balla, G.; Jessurun, J.; Jacob, H.S.; Vercellotti, G.M. Ferritin protects endothelial cells from oxidized low density lipoprotein in vitro. Am. J. Pathol. 1995, 147, 782–789.
107. Lee, F.Y.; Lee, T.S.; Pan, C.C.; Huang, A.L.; Chau, L.Y. Colocalization of iron and ceroid in human atherosclerotic lesions. Atherosclerosis 1998, 138, 281–288.
108. Baldwin, A.L. Modified hemoglobins produce venular interendothelial gaps and albumin leakage in the rat mesentery. Am. J. Physiol. 1999, 277, H650–H659.
109. Abela, G.S.; Aziz, K.; Vedre, A.; Pathak, D.R.; Talbott, J.D.; Dejong, J. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am. J. Cardiol. 2009, 103, 959–968.
110. Kaartinen, M.; Penttila, A.; Kovanen, P.T. Mast cells accompany microvessels in human coronary atheromas: Implications for intimal neovascularization and hemorrhage. Atherosclerosis 1996, 123, 123–131.
111. Ambrose, J.A.; Tannenbaum, M.A.; Alexopoulos, D.; Hjemdahl-Monsen, C.E.; Leavy, J.; Weiss, M.; Borrico, S.; Gorlin, R.; Fuster, V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J. Am. Coll. Cardiol. 1988, 12, 56–62.
112. Hyafil, F.; Cornily, J.C.; Feig, J.E.; Gordon, R.; Vucic, E.; Amirbekian, V.; Fisher, E.A.; Fuster, V.; Feldman, L.J.; Fayad, Z.A. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 2007, 13, 636–641.
113. Romero, J.M.; Pizzolato, R.; Atkinson, W.; Meader, A.; Jaimes, C.; Lamuraglia, G.; Jaff, M.R.; Buonanno, F.; Delgado Almandoz, J.; Gonzalez, R.G. Vasa vasorum enhancement on computerized tomographic angiography correlates with symptomatic patients with 50% to 70% carotid artery stenosis. Stroke J. Cereb. Circ. 2013, 44, 3344–3349.
114. Sadeghi, M.M.; Glover, D.K.; Lanza, G.M.; Fayad, Z.A.; Johnson, L.L. Imaging atherosclerosis and vulnerable plaque. J. Nucl. Med. 2010, 51, 51S–65S.
115. Li, W.; van der Steen, A.F.; Lancee, C.T.; Cespedes, I.; Bom, N. Blood flow imaging and volume flow quantitation with intravascular ultrasound. Ultrasound Med. Biol. 1998, 24, 203–214.
116. Moritz, R.; Eaker, D.R.; Anderson, J.L.; Kline, T.L.; Jorgensen, S.M.; Lerman, A.; Ritman, E.L. IVUS detection of vasa vasorum blood flow distribution in coronary artery vessel wall. JACC Cardiovasc. Imaging 2012, 5, 935–940.
117. Papaioannou, T.G.; Vavuranakis, M.; Androulakis, A.; Lazaros, G.; Kakadiaris, I.; Vlaseros, I.; Naghavi, M.; Kallikazaros, I.; Stefanadis, C. In-vivo imaging of carotid plaque neoangiogenesis with contrast-enhanced harmonic ultrasound. Int. J. Cardiol. 2009, 134, e110–e112.
118. O’Malley, S.M.; Vavuranakis, M.; Naghavi, M.; Kakadiaris, I.A. Intravascular ultrasound-based imaging of vasa vasorum for the detection of vulnerable atherosclerotic plaque. Med. Image Comput. Comput. Assist. Interv. MICCAI 2005, 8 Pt 1, 343–351.
119. Vavuranakis, M.; Kakadiaris, I.A.; O’Malley, S.M.; Papaioannou, T.G.; Sanidas, E.A.; Naghavi, M.; Carlier, S.; Tousoulis, D.; Stefanadis, C. A new method for assessment of plaque vulnerability based on vasa vasorum imaging, by using contrast-enhanced intravascular ultrasound and differential image analysis. Int. J. Cardiol. 2008, 130, 23–29.
120. Goertz, D.E.; Frijlink, M.E.; Tempel, D.; van Damme, L.C.; Krams, R.; Schaar, J.A.; Ten Cate, F.J.; Serruys, P.W.; de Jong, N.; van der Steen, A.F. Contrast harmonic intravascular ultrasound: A feasibility study for vasa vasorum imaging. Investig. Radiol. 2006, 41, 631–638.
121. Goertz, D.E.; Frijlink, M.E.; Tempel, D.; Bhagwandas, V.; Gisolf, A.; Krams, R.; de Jong, N.; van der Steen, A.F. Subharmonic contrast intravascular ultrasound for vasa vasorum imaging. Ultrasound Med. Biol. 2007, 33, 1859–1872.
122. Goertz, D.E.; Frijlink, M.E.; de Jong, N.; van der Steen, A.F. Nonlinear intravascular ultrasound contrast imaging. Ultrasound Med. Biol. 2006, 32, 491–502.
123. Magnoni, M.; Coli, S.; Marrocco-Trischitta, M.M.; Melisurgo, G.; de Dominicis, D.; Cianflone, D.; Chiesa, R.; Feinstein, S.B.; Maseri, A. Contrast-enhanced ultrasound imaging of periadventitial vasa vasorum in human carotid arteries. Eur. J. Echocardiogr. 2009, 10, 260–264.
124. Shah, F.; Balan, P.; Weinberg, M.; Reddy, V.; Neems, R.; Feinstein, M.; Dainauskas, J.; Meyer, P.; Goldin, M.; Feinstein, S.B. Contrast-enhanced ultrasound imaging of atherosclerotic carotid plaque neovascularization: A new surrogate marker of atherosclerosis? Vasc. Med. 2007, 12, 291–297.
125. Schinkel, A.F.; Krueger, C.G.; Tellez, A.; Granada, J.F.; Reed, J.D.; Hall, A.; Zang, W.; Owens, C.; Kaluza, G.L.; Staub, D.; et al. Contrast-enhanced ultrasound for imaging vasa vasorum: Comparison with histopathology in a swine model of atherosclerosis. Eur. J. Echocardiogr. 2010, 11, 659–664.
126. Coli, S.; Magnoni, M.; Sangiorgi, G.; Marrocco-Trischitta, M.M.; Melisurgo, G.; Mauriello, A.; Spagnoli, L.; Chiesa, R.; Cianflone, D.; Maseri, A. Contrast-enhanced ultrasound imaging of intraplaque neovascularization in carotid arteries: Correlation with histology and plaque echogenicity. J. Am. Coll. Cardiol. 2008, 52, 223–230.
127. Lee, S.C.; Carr, C.L.; Davidson, B.P.; Ellegala, D.; Xie, A.; Ammi, A.; Belcik, T.; Lindner, J.R. Temporal characterization of the functional density of the vasa vasorum by contrast-enhanced ultrasonography maximum intensity projection imaging. JACC Cardiovasc. Imaging 2010, 3, 1265–1272.
128. Moguillansky, D.; Leng, X.; Carson, A.; Lavery, L.; Schwartz, A.; Chen, X.; Villanueva, F.S. Quantification of plaque neovascularization using contrast ultrasound: A histologic validation. Eur. Heart J. 2011, 32, 646–653.
129. Tian, J.; Hu, S.; Sun, Y.; Yu, H.; Han, X.; Cheng, W.; Ban, X.; Zhang, S.; Yu, B.; Jang, I.K. Vasa vasorum and plaque progression, and responses to atorvastatin in a rabbit model of atherosclerosis: Contrast-enhanced ultrasound imaging and intravascular ultrasound study. Heart 2013, 99, 48–54.
130. Deyama, J.; Nakamura, T.; Takishima, I.; Fujioka, D.; Kawabata, K.; Obata, J.E.; Watanabe, K.; Watanabe, Y.; Saito, Y.; Mishina, H.; et al. Contrast-enhanced ultrasound imaging of carotid plaque neovascularization is useful for identifying high-risk patients with coronary artery disease. Circ. J. 2013, 77, 1499–1507.
131. Vavuranakis, M.; Sigala, F.; Vrachatis, D.A.; Papaioannou, T.G.; Filis, K.; Kavantzas, N.; Kalogeras, K.I.; Massoura, C.; Toufektzian, L.; Kariori, M.G.;et al. Quantitative analysis of carotid plaque vasa vasorum by CEUS and correlation with histology after endarterectomy. VASA Z. Gefasskrankh. 2013, 42, 184–195.
132. Kubo, T.; Tanaka, A.; Ino, Y.; Kitabata, H.; Shiono, Y.; Akasaka, T. Assessment of coronary atherosclerosis using optical coherence tomography. J. Atheroscler. Thromb. 2014, 21, 895–903.
133. Kume, T.; Akasaka, T.; Kawamoto, T.; Watanabe, N.; Toyota, E.; Neishi, Y.; Sukmawan, R.; Sadahira, Y.; Yoshida, K. Assessment of coronary intima—Media thickness by optical coherence tomography: Comparison with intravascular ultrasound. Circ. J. 2005, 69, 903–907.
134. Kitabata, H.; Tanaka, A.; Kubo, T.; Takarada, S.; Kashiwagi, M.; Tsujioka, H.; Ikejima, H.; Kuroi, A.; Kataiwa, H.; Ishibashi, K.; et al. Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. Am. J. Cardiol. 2010, 105, 1673–1678.
135. Cheng, K.H.; Sun, C.; Vuong, B.; Lee, K.K.; Mariampillai, A.; Marotta, T.R.; Spears, J.; Montanera, W.J.; Herman, P.R.; Kiehl, T.R.; et al. Endovascular optical coherence tomography intensity kurtosis: Visualization of vasa vasorum in porcine carotid artery. Biomed. Opt. Express 2012, 3, 388–399.
136. Tearney, G.J.; Regar, E.; Akasaka, T.; Adriaenssens, T.; Barlis, P.; Bezerra, H.G.; Bouma, B.; Bruining, N.; Cho, J.M.; Chowdhary, S.; et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J. Am. Coll. Cardiol. 2012, 59, 1058–1072.
137. Nishimiya, K.; Matsumoto, Y.; Takahashi, J.; Uzuka, H.; Odaka, Y.; Nihei, T.; Hao, K.; Tsuburaya, R.; Ito, K.; Shimokawa, H. In vivo visualization of adventitial vasa vasorum of the human coronary artery on optical frequency domain imaging. Validation study. Circ. J. 2014, 78, 2516–2518.
138. Aoki, T.; Rodriguez-Porcel, M.; Matsuo, Y.; Cassar, A.; Kwon, T.G.; Franchi, F.; Gulati, R.; Kushwaha, S.S.; Lennon, R.J.; Lerman, L.O.; et al. Evaluation of coronary adventitial vasa vasorum using 3D optical coherence tomography—Animal and human studies. Atherosclerosis 2015, 239, 203–208.
139. Dobrucki, L.W.; Sinusas, A.J. PET and SPECT in cardiovascular molecular imaging. Nat. Rev. Cardiol. 2010, 7, 38–47.
140. 18 F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 2006, 48, 1818–1824.
141. 18 Fluorine-labeled 2-deoxy-D-glucose positron emission tomography. J. Am. Coll. Cardiol. 2011, 58, 603–614.
142. Rodriguez-Porcel, M.; Cai, W.; Gheysens, O.; Willmann, J.K.; Chen, K.; Wang, H.; Chen, I.Y.; He, L.; Wu, J.C.; Li, Z.B.;et al. Imaging of VEGF receptor in a rat myocardial infarction model using PET. J. Nucl. Med. 2008, 49, 667–673.
143. Meoli, D.F.; Sadeghi, M.M.; Krassilnikova, S.; Bourke, B.N.; Giordano, F.J.; Dione, D.P.; Su, H.; Edwards, D.S.; Liu, S.; Harris, T.D.; et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J. Clin. Investig. 2004, 113, 1684–1691.
144. Janssen, M.L.; Oyen, W.J.; Dijkgraaf, I.; Massuger, L.F.; Frielink, C.; Edwards, D.S.; Rajopadhye, M.; Boonstra, H.; Corstens, F.H.; Boerman, O.C. Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model. Cancer Res. 2002, 62, 6146–6151.
145. Kopka, K.; Breyholz, H.J.; Wagner, S.; Law, M.P.; Riemann, B.; Schroer, S.; Trub, M.; Guilbert, B.; Levkau, B.; Schober, O.; et al. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl. Med. Biol. 2004, 31, 257–267.
146. 18 F-labeled matrix metalloproteinase-2 inhibitor. Nucl.Med. Biol. 2003, 30, 119–125.
147. Schafers, M.; Riemann, B.; Kopka, K.; Breyholz, H.J.; Wagner, S.; Schafers, K.P.; Law, M.P.; Schober, O.; Levkau, B. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004, 109, 2554–2559.
148. Matter, C.M.; Schuler, P.K.; Alessi, P.; Meier, P.; Ricci, R.; Zhang, D.; Halin, C.; Castellani, P.; Zardi, L.; Hofer, C.K.; et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ. Res. 2004, 95, 1225–1233.
149. Kuge, Y.; Takai, N.; Ogawa, Y.; Temma, T.; Zhao, Y.; Nishigori, K.; Ishino, S.; Kamihashi, J.; Kiyono, Y.; Shiomi, M.; et al. Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: Potentials for characterizing atherosclerotic plaques. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 2093–2104.
150. Aoki, S.; Aoki, K.; Ohsawa, S.; Nakajima, H.; Kumagai, H.; Araki, T. Dynamic MR imaging of the carotid wall. J. Magn. Reson. Imaging JMRI 1999, 9, 420–427.
151. Winter, P.M.; Morawski, A.M.; Caruthers, S.D.; Fuhrhop, R.W.; Zhang, H.; Williams, T.A.; Allen, J.S.; Lacy, E.K.; Robertson, J.D.; Lanza, G.M.; et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with αvβ3-integrin-targeted nanoparticles. Circulation 2003, 108, 2270–2274.
152. Cai, K.; Caruthers, S.D.; Huang, W.; Williams, T.A.; Zhang, H.; Wickline, S.A.; Lanza, G.M.; Winter, P.M. MR molecular imaging of aortic angiogenesis. JACC Cardiovasc. Imaging 2010, 3, 824–832.
153. Kerwin, W.; Hooker, A.; Spilker, M.; Vicini, P.; Ferguson, M.; Hatsukami, T.; Yuan, C. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 2003, 107, 851–856.
154. Kerwin, W.S.; Oikawa, M.; Yuan, C.; Jarvik, G.P.; Hatsukami, T.S. MR imaging of adventitial vasa vasorum in carotid atherosclerosis. Magn. Reson. Med. 2008, 59, 507–514.
155. Sun, J.; Song, Y.; Chen, H.; Kerwin, W.S.; Hippe, D.S.; Dong, L.; Chen, M.; Zhou, C.; Hatsukami, T.S.; Yuan, C. Adventitial perfusion and intraplaque hemorrhage: A dynamic contrast-enhanced MRI study in the carotid artery. Stroke J. Cereb. Circ. 2013, 44, 1031–1036.
156. Grobner, T. Gadolinium—A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol. Dial. Transpl. 2006, 21, 1104–1108.
157. Feinstein, S.B. Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. J. Am. Coll. Cardiol. 2006, 48, 236–243.
158. Decano, J.L.; Moran, A.M.; Ruiz-Opazo, N.; Herrera, V.L. Molecular imaging of vasa vasorum neovascularization via DEspR-targeted contrast-enhanced ultrasound micro-imaging in transgenic atherosclerosis rat model. Mol. Imaging Biol. MIB 2011, 13, 1096–1106.
159. Baron Toaldo, M.; Salvatore, V.; Marinelli, S.; Palama, C.; Milazzo, M.; Croci, L.; Venerandi, L.; Cipone, M.; Bolondi, L.; Piscaglia, F. Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. Mol. Imaging Biol. MIB 2015, 17, 29–37.
160. Araldi, E.; Chamorro-Jorganes, A.; van Solingen, C.; Fernandez-Hernando, C.; Suarez, Y. Therapeutic potential of modulating microRNAs in atherosclerotic vascular disease. Curr. Vasc. Pharmacol. 2013, in press.
161. O’Reilly, M.S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R.A.; Moses, M.; Lane, W.S.; Cao, Y.; Sage, E.H.; Folkman, J. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79, 315–328.
162. O’Reilly, M.S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W.S.; Flynn, E.; Birkhead, J.R.; Olsen, B.R.; Folkman, J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88, 277–285.
163. Moulton, K.S.; Heller, E.; Konerding, M.A.; Flynn, E.; Palinski, W.; Folkman, J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999, 99, 1726–1732.
164. Moulton, K.S.; Vakili, K.; Zurakowski, D.; Soliman, M.; Butterfield, C.; Sylvin, E.; Lo, K.M.; Gillies, S.; Javaherian, K.; Folkman, J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc. Natl. Acad. Sci. USA 2003, 100, 4736–4741.
165. Eriksson, K.; Magnusson, P.; Dixelius, J.; Claesson-Welsh, L.; Cross, M.J. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett. 2003, 536, 19–24.
166. Stefanadis, C.; Toutouzas, K.; Stefanadi, E.; Kolodgie, F.; Virmani, R.; Kipshidze, N. First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: Angiographic results in a rabbit atheromatic model. Hell. J. Cardiol. HJC 2006, 47, 7–10.
167. Luttun, A.; Tjwa, M.; Moons, L.; Wu, Y.; Angelillo-Scherrer, A.; Liao, F.; Nagy, J.A.; Hooper, A.; Priller, J.; de Klerck, B.; et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 2002, 8, 831–840.
168. Khurana, R.; Moons, L.; Shafi, S.; Luttun, A.; Collen, D.; Martin, J.F.; Carmeliet, P.; Zachary, I.C. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005, 111, 2828–2836.
169. Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos, E.; Liesenborghs, L.; Koch, M.; de Mol, M.; et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitorresistant tumors without affecting healthy vessels. Cell 2007, 131, 463–475.
170. Johnson, M.D.; Kim, H.R.; Chesler, L.; Tsao-Wu, G.; Bouck, N.; Polverini, P.J. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J. Cell. Physiol. 1994, 160, 194–202.
171. Gossl, M.; Herrmann, J.; Tang, H.; Versari, D.; Galili, O.; Mannheim, D.; Rajkumar, S.V.; Lerman, L.O.; Lerman, A. Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. Basic Res. Cardiol. 2009, 104, 695–706.
172. −/− double knockout mice: A nano-CT study. Int. J. Cardiovasc. Imaging 2014, 30, 795–802.
173. Dashwood, M.R.; Barker, S.G.; Muddle, J.R.; Yacoub, M.H.; Martin, J.F. [125I]-endothelin-1 binding to vasa vasorum and regions of neovascularization in human and porcine blood vessels: A possible role for endothelin in intimal hyperplasia and atherosclerosis. J. Cardiovasc. Pharmacol. 1993, 22, S343–S347.
174. Herrmann, J.; Best, P.J.; Ritman, E.L.; Holmes, D.R.; Lerman, L.O.; Lerman, A. Chronic endothelin receptor antagonism prevents coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J. Am. Coll. Cardiol. 2002, 39, 1555–1561.
175. Winter, P.M.; Neubauer, A.M.; Caruthers, S.D.; Harris, T.D.; Robertson, J.D.; Williams, T.A.; Schmieder, A.H.; Hu, G.; Allen, J.S.; Lacy, E.K.;et al. Endothelial αvβ3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2103–2109.
176. Drinane, M.; Mollmark, J.; Zagorchev, L.; Moodie, K.; Sun, B.; Hall, A.; Shipman, S.; Morganelli, P.; Simons, M.; Mulligan-Kehoe, M.J. The antiangiogenic activity of rPAI-123 inhibits vasa vasorum and growth of atherosclerotic plaque. Circ. Res. 2009, 104, 337–345.
177. Mollmark, J.; Ravi, S.; Sun, B.; Shipman, S.; Buitendijk, M.; Simons, M.; Mulligan-Kehoe, M.J. Antiangiogenic activity of rPAI-123 promotes vasa vasorum regression in hypercholesterolemic mice through a plasmin-dependent mechanism. Circ. Res. 2011, 108, 1419–1428.
178. −/− double knockout mice. Atherosclerosis 2009, 202, 103–110.
179. Tsai, H.T.; Marshall, J.L.; Weiss, S.R.; Huang, C.Y.; Warren, J.L.; Freedman, A.N.; Fu, A.Z.; Sansbury, L.B.; Potosky, A.L. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: A population-based study. Ann. Oncol. 2013, 24, 1574–1579.
180. Colon, G.P.; Deveikis, J.P.; Dickinson, L.D. Revascularization of occluded internal carotid arteries by hypertrophied vasa vasorum: Report of four cases. Neurosurgery 1999, 45, 634–637.
181. Shanahan, C.M.; Weissberg, P.L. Smooth muscle cell phenotypes in atherosclerotic lesions. Curr. Opin. Lipidol. 1999, 10, 507–513.
182. Wilson, S.H.; Herrmann, J.; Lerman, L.O.; Holmes, D.R., Jr.; Napoli, C.; Ritman, E.L.; Lerman, A. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002, 105, 415–418.
183. Urbich, C.; Dernbach, E.; Zeiher, A.M.; Dimmeler, S. Double-edged role of statins in angiogenesis signaling. Circ. Res. 2002, 90, 737–744.
184. Chaldakov, G.N.; Stankulov, I.S.; Fiore, M.; Ghenev, P.I.; Aloe, L. Nerve growth factor levels and mast cell distribution in human coronary atherosclerosis. Atherosclerosis 2001, 159, 57–66.
185. Asanome, A.; Kawabe, J.; Matsuki, M.; Kabara, M.; Hira, Y.; Bochimoto, H.; Yamauchi, A.; Aonuma, T.; Takehara, N.; Watanabe, T.; et al. Nerve growth factor stimulates regeneration of perivascular nerve, and induces the maturation of microvessels around the injured artery. Biochem. Biophys. Res. Commun. 2014, 443, 150–155.
186. Mollmark, J.I.; Park, A.J.; Kim, J.; Wang, T.Z.; Katzenell, S.; Shipman, S.L.; Zagorchev, L.G.; Simons, M.; Mulligan-Kehoe, M.J. Fibroblast growth factor-2 is required for vasa vasorum plexus stability in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2644–2651.
187. Lindner, V.; Lappi, D.A.; Baird, A.; Majack, R.A.; Reidy, M.A. Role of basic fibroblast growth factor in vascular lesion formation. Circ. Res. 1991, 68, 106–113.
188. Six, I.; Mouquet, F.; Corseaux, D.; Bordet, R.; Letourneau, T.; Vallet, B.; Dosquet, C.C.; Dupuis, B.; Jude, B.; Bertrand, M.E.; et al. Protective effects of basic fibroblast growth factor in early atherosclerosis. Growth Factors 2004, 22, 157–167.
189. Che, J.; Okigaki, M.; Takahashi, T.; Katsume, A.; Adachi, Y.; Yamaguchi, S.; Matsunaga, S.; Takeda, M.; Matsui, A.; Kishita, E.; et al. Endothelial FGF receptor signaling accelerates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol. 2011, 300, H154–H161.
190. Shen, W.; Shi, H.M.; Fan, W.H.; Luo, X.P.; Jin, B.; Li, Y. The effects of simvastatin on angiogenesis: Studied by an original model of atherosclerosis and acute myocardial infarction in rabbit. Mol. Biol. Rep. 2011, 38, 3821–3828.